Prophylactic pasireotide administration following pancreatic resection reduces cost while improving outcomes.

about

Selective Perioperative Administration of Pasireotide is More Cost-Effective Than Routine Administration for Pancreatic Fistula Prophylaxis.Cost-effectiveness comparison of prophylactic octreotide and pasireotide for prevention of fistula after pancreatic surgery.

P2860

Q36239183-EEF56298-362B-40D7-B515-659FE35FE8FF Q38846157-4BDACED4-6C1B-4A74-A28A-1BAA89FB1FA4

P2860

Prophylactic pasireotide administration following pancreatic resection reduces cost while improving outcomes.

Item

http://www.wikidata.org/entity/Q40729981

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh

2016年學術文章

@zh-hant

name

Prophylactic pasireotide admin ...... cost while improving outcomes.

@en

type

Item

label

Prophylactic pasireotide admin ...... cost while improving outcomes.

@en

prefLabel

Prophylactic pasireotide admin ...... cost while improving outcomes.

@en

P1476

Prophylactic pasireotide admin ...... cost while improving outcomes

@en

P2093

Alex Chang

http://www.w3.org/2001/XMLSchema#string

Daniel E Abbott

http://www.w3.org/2001/XMLSchema#string

Daniel P Schauer

http://www.w3.org/2001/XMLSchema#string

Jeffrey J Sussman

http://www.w3.org/2001/XMLSchema#string

Jeffrey M Sutton

http://www.w3.org/2001/XMLSchema#string

Patrick Frye

http://www.w3.org/2001/XMLSchema#string

Peter L Jernigan

http://www.w3.org/2001/XMLSchema#string

Shimul A Shah

http://www.w3.org/2001/XMLSchema#string

Syed A Ahmad

http://www.w3.org/2001/XMLSchema#string

P2860

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

Pancreatic anastomotic failure rate after pancreaticoduodenectomy decreases with microsurgery.

Assessment of health care cost for complex surgical patients: review of cost, re-imbursement and revenue involved in pancreatic surgery at a high-volume academic medical centre.

Major pancreatic resections for suspected cancer in a community-based teaching hospital: lessons learned.

Cost-effectiveness of folfirinox for first-line treatment of metastatic pancreatic cancer.

Influence of patient, physician, and hospital factors on 30-day readmission following pancreatoduodenectomy in the United States.

Does prophylactic octreotide decrease the rates of pancreatic fistula and other complications after pancreaticoduodenectomy? Results of a prospective randomized placebo-controlled trial.

The Association Between Hospital Finances and Complications After Complex Abdominal Surgery: Deficiencies in the Current Health Care Reimbursement System and Implications for the Future.

Updating Cost Effectiveness Analyses in Orthopedic Surgery: Resilience of the $50,000 per QALY Threshold.

Prospective, randomized trial of octreotide to prevent pancreatic fistula after pancreaticoduodenectomy for malignant disease.

P304

784-788

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/JSO.24239

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

113

http://www.w3.org/2001/XMLSchema#string

P50

Mark H Eckman

P577

2016-04-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27041733

http://www.w3.org/2001/XMLSchema#string

Prophylactic pasireotide administration following pancreatic resection reduces cost while improving outcomes.

about

P2860

P2860

Prophylactic pasireotide administration following pancreatic resection reduces cost while improving outcomes.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698